Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 13 Oct 2022 UCB announces positive preliminary results for major brivaracetam (Briviact[®]) study in Asia Read More 27 Sep 2022 FINTEPLA[®▼] (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome Read More 23 Sep 2022 Disposal of own shares Read More 22 Sep 2022 UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting Read More 20 Sep 2022 European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Read More 9 Sep 2022 Disposal of own shares Read More Pagination First page Previous page Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
